title: [Methylprednisolone as an antiemetic in the chemotherapy of ovarian cancer].
abstract: The authors examined the antiemetic effect of methylprednisolone (Lemod Solu) of the firm "Upjoh" in 35 patients with ovarian cancer in the course of the cisplatinum therapy. The control group comprised 15 patients with the same degree of ovarian cancer spreading in whom metoclopramide was used as the antiemetic. The antiemetic effect of methylprednisolone was found in the three fifths of patients having received the preparation from the first cisplatinum therapy cycle and in more than half of those in whom methylprednisolone was included in the second or third cisplatinum therapy cycle. The antiemetic effect of methylprednisolone proved to be significantly better than that of metoclopramide whose antiemetic effect was recorded in one fifth of the patients.
authors.forename: L
authors.initials: L
authors.lastname: Jokanović
authors.forename: P
authors.initials: P
authors.lastname: Klarić
authors.forename: L
authors.initials: L
authors.lastname: Benković
mesh_terms: D000932:Antiemetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use*; D008787:Metoclopramide / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D008787:Metoclopramide; D008775:Methylprednisolone
vernacular_title: Metilprednizolon kao antiemetik uz kemoterapiju raka jajnika.